Erlina Burhan
Universitas Indonesia

Published : 5 Documents Claim Missing Document
Claim Missing Document

Found 5 Documents

Inflammatory Markers upon Admission as Predictors of Outcome in COVID-19 Patients Budhi Antariksa; Erlina Burhan; Agus Dwi Susanto; Mohamad Fahmi Alatas; Feni Fitriani Taufik; Dewi Yennita Sari; Dicky Soehardiman; Andika Chandra Putra; Erlang Samoedro; Ibrahim Nur Insan Putra Darmawan; Hera Afidjati; Muhammad Alkaff; Rita Rogayah
Jurnal Respirologi Indonesia Vol 41, No 4 (2021)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v41i4.185


Background: Coronavirus disease 2019 (COVID-19) may cause dysregulation of the immune system, leading to hyperinflammation. Inflammatory markers can be used to predict in-hospital mortality in COVID-19 patients. This research was aimed to investigate the association between the levels of various inflammatory markers and mortality in COVID-19 patients.Methods: This study was conducted at Persahabatan National Respiratory Referral Hospital, Indonesia. Blood tests were performed upon admission, measuring the C-reactive protein, PCT, leukocyte, differential counts, and platelet count. The outcome measured was the mortality of hospitalized COVID-19 patients. Statistical analysis methods included the Mann–Whitney U test, receiver operating characteristic (ROC) analysis, and area under the curve (AUC) test.Results: Total 110 patients were included, and the laboratory values were analyzed to compare survivors and non-survivors. The non-survivor group had significantly higher leukocyte count, lower lymphocyte count, higher CRP and PCT levels, higher neutrophil-to-lymphocyte ratio (NLR), higher platelet-to-lymphocyte ratio (PLR), and lower lymphocyte-to-CRP ratio. As predictors of mortality, AUC analysis revealed that PCT, CRP, NLR, and PLR had AUCs of 0.867, 0.82, 0.791, and 0.746, respectively.Conclusions: Routine and affordable inflammatory markers tested on admission may be useful as predictors of in-hospital mortality in COVID-19 patients requiring hospitalization.
The Proportion of Latent Tuberculosis Infection in Naive Lung Cancer Patients at Persahabatan Hospital Jakarta Erlina Burhan; Ririen Razika Ramdhani; Jamal Zaini
Jurnal Respirologi Indonesia Vol 39, No 4 (2019)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v39i4.73


Background: Lung cancer and pulmonary tuberculosis (TB) are two major public health problems associated with significant morbidities and mortalities. The increased prevalence of active TB and latent TB reactivation in lung cancer patients and negative effect of pulmonary TB in lung cancer prognosis needed screening of lung cancer patients for latent TB infection (LTBI). This study aimed to determine the proportion of LTBI in lung cancer patients, their characteristics and the relationship between them. Methods: This study used cross-sectional design. Collecting sample used consecutive sampling of 86 newly diagnosed treatment-naive lung cancer patients from RSUP Persahabatan in 2015 to 2016. The presence of LTBI was determined by Quantiferon-TB Gold-In-Tube (QFT- GIT) after having Mycobacterium TB not detected result from Xpert MTB/RIF sputum test. Demographic characteristics and cancer-related factors associated with LTBI were investigated. Results: The results of latent TB tests were IGRA(+) 12.8%, IGRA(-) 68.6% and IGRA(I) 18.6%. Number of male patients with lung cancer with latent were 68.6%, as many as 55.8% were immunized with BCG, 4.6% had close contact with TB and 64% were using smoking. Most types of cancer were adenocarcinomas (77.9%) with advanced stage (82.6%) and general display status 2 (50%). The characteristics that show an association with IGRA results are the location of the cancer and the total lymphocyte count. Conclusion: The proportion of latent TB in lung cancer patients at the RSUP Persahabatan was 12.8%. The location of the cancer associated with the area of typical TB was related to latent TB, although it cannot be canceled. Results of IGRA(I) in lung cancer patients with low total lymphocyte counts prove IGRA sensitivity in the protection of latent TB infection in immunocompromised patients. (J Respir Indo. 2019; 39(4): 256-65)
Corona Virus Disease 2019 Diah Handayani; Dwi Rendra Hadi; Fathiyah Isbaniah; Erlina Burhan; Heidy Agustin
Jurnal Respirologi Indonesia Vol 40, No 2 (2020)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v40i2.101


Corona virus disease 2019 (COVID-19) is a new name given by World Health Organization (WHO) of 2019 novel corona virus infection, reported at the end of 2019 from Wuhan, Cina. The spread of infection occurs rapidly and creates a new pandemic threat. Etiology of COVID-19 was identified in 10 January 2020, a betacorona virus, similar with severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS CoV). The clue diagnosis pathway of COVID-19 were history of travel from Wuhan or others infected countries within 14 days prior, and symptoms of acute respiratory illness (ARI) or lower respiratory infection (pneumonia) with the result of real time polymerase chain reaction (RT-PCR) specific for COVID-19. The WHO classified COVID-19 into suspect case, probable case and confirmed case. Indonesia Ministry of Health classified the case into in monitoring (ODP), patient under surveillance (PDP), people without symptom (OTG) and confirmed case. Specimens for detection COVID-19 could be acquired from nasal and nasopharynx swab, sputum and another lower respiratory aspirate including broncoalveolar lavage (BAL). Management of COVID-19 consist of isolation and infection control, supportive treatment according to the disease severity which could be mild (acute respiratory infection) to severe pneumonia or acute respiratory distress syndrome (ARDS). Disease transmission is via droplets and contact with droplets. Currently, there is no antiviral and vaccine. Prevention is very important for this disease by limitation of transmission, identification and isolate patients. Prognosis is determined by severity of the disease and patient comorbidity. Information about this novel disease remains very few, studies are still ongoing and is needing further research to fight with this new virus. (J Respir Indo. 2020; 40(2): 120-30)
Type 2 Diabetes Mellitus And Hemoptisis Risk Factor In Lung Tuberculosis : A Case Control Study Widhy Yudistira Nalapraya; Jaka Pradipta; Muhammad Ikhsan Mokoagow; Erlina Burhan
Jurnal Respirologi Indonesia Vol 40, No 3 (2020)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v40i3.111


Background: Diabetes mellitus (DM) is a risk factor for tuberculosis (TB) morbidity and mortality. Increasing cases of type 2 DM in the world increases the risk of developing TB. The frequency of DM in TB patients was reported to be around 10-15% and the prevalence of this infectious disease was 2-5 times higher in diabetic patients compared to non-diabetics. Hemoptysis is a respiratory symptom which can be life threatening. Tuberculosis and bronchiectasis are the two most common ethology of hemoptysis, while TB with DM are the cause of recurrent hemoptysis. Methods: This was case control study which used the medical records data of diabetic patients infected with TB who experienced hemoptysis and no hemoptysis, treated at Fatmawati General Hospital during 2017. Sampling method was total sampling. Results: There were 12 hemoptysis patients with DM comorbidity and 31 patients without DM comorbidity. As many as 58% of patients with DM had new cases of pulmonary TB and 42% had history of treatment completion. The correlation between hemoptysis of TB patients with DM compared to without DM obtained a relative risk of 1.535 (95% CI=0.677-2.618) Conclusion: The proportion of hemoptysis in TB patients with DM comorbidity was 10.3%. Diabetes Mellitus was a risk factor for hemoptysis 1.535 times higher compared to TB patients without DM but statistically not significant. (J Respir Indo. 2020; 40(3): 144-9)
Pulmonary Mycoses in Indonesia: Current Situations and Future Challenges Anna Rozaliyani; Anwar Jusuf; Priyanti ZS; Erlina Burhan; Diah Handayani; Henie Widowati; Satria Pratama; Findra Setianingrum
Jurnal Respirologi Indonesia Vol 39, No 3 (2019)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (900.239 KB) | DOI: 10.36497/jri.v39i3.69


Cases of pulmonary mycosis or pulmonary fungal diseases continues to increase in frequency along with the expanding population with impaired immune systems, including patients with pre-existing pulmonary diseases. Changing profile of underlying diseases might cause altering diseases profile as well. In previous decades, Pneumocystis pneumonia was the most common pulmonary mycosis in HIV-infected patients. As the increasing number of TB cases, pulmonary malignancy, chronic obstructive pulmonary disease (COPD) and certain chronic diseases, other pulmonary mycoses also increase such as chronic pulmonary aspergillosis, cryptococcosis, histoplasmosis, and other filamentous fungal infection. Furthermore, the airborne fungal particles of Aspergillus and other fungi could seriously worsen asthma or allergic respiratory diseases. In low- and middle-income countries, including Indonesia, lack of diagnostic facilities may lead to inadequate treatment. It will contribute to poor clinical outcomes with high mortality rates. The awareness among clinicians and other health workers of this epidemiology changes is the important step in early diagnosis and better managemenet of pulmonary mycosis in the future. (J Respir Indo. 2019; 39(3): 210-4)